^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:cemacabtagene ansegedleucel (ALLO-501A) (CD19-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Allogene Therapeutics Press Release
    Title:

    Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

    Published date:
    02/25/2021
    Excerpt:
    ALLO-501A Granted FDA Fast Track Designation for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL), a Type of NHL.